Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.42 |
| ▸ | CYBB | P04839 | 1/20 | 0.42 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.42 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755138 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL6755137 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL6997145 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL3618121 | 0.85 | POLB (0.47) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL8523594 | 0.81 | LMNA (0.50) | SMN1; SMN2POLBKMT2ALMNAHTT | |
| SCHEMBL10649973 | 0.78 | POLB (0.50) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL6203711 | 0.78 | POLB (0.50) | SMN1; SMN2POLBHDAC1HDAC8HDAC6 | |
| SCHEMBL7386855 | 0.77 | KMT2A (0.42) | KMT2AMEN1KIF11 | |
| SCHEMBL7386852 | 0.77 | KMT2A (0.42) | KMT2AMEN1KIF11 | |
| SCHEMBL7382649 | 0.77 | KMT2A (0.42) | KMT2AMEN1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0966473-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-24 | — | — | EP | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | SMN1; SMN2 4135/4885POLB 301/4885HDAC1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.